MA30175B1 - Ligands qui lient il-4 et/ou il-13 - Google Patents

Ligands qui lient il-4 et/ou il-13

Info

Publication number
MA30175B1
MA30175B1 MA31143A MA31143A MA30175B1 MA 30175 B1 MA30175 B1 MA 30175B1 MA 31143 A MA31143 A MA 31143A MA 31143 A MA31143 A MA 31143A MA 30175 B1 MA30175 B1 MA 30175B1
Authority
MA
Morocco
Prior art keywords
ligands
bind
interleukin
treatment
invention concerns
Prior art date
Application number
MA31143A
Other languages
English (en)
French (fr)
Inventor
Ian Tomlinson
Adriaan Allart Stoop
Armin Sepp
Silva Inusha De
Caroline J Dimech
Malgorzata Pupecka
Wildt Rudolf M T De
Philip D Drew
Steve Holmes
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of MA30175B1 publication Critical patent/MA30175B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA31143A 2006-01-24 2008-07-25 Ligands qui lient il-4 et/ou il-13 MA30175B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76170806P 2006-01-24 2006-01-24

Publications (1)

Publication Number Publication Date
MA30175B1 true MA30175B1 (fr) 2009-01-02

Family

ID=38028503

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31143A MA30175B1 (fr) 2006-01-24 2008-07-25 Ligands qui lient il-4 et/ou il-13

Country Status (16)

Country Link
US (3) US20110159003A1 (OSRAM)
EP (1) EP1976882A2 (OSRAM)
JP (2) JP2009523459A (OSRAM)
KR (1) KR20080098382A (OSRAM)
CN (1) CN101578298A (OSRAM)
AU (1) AU2007209202A1 (OSRAM)
BR (1) BRPI0710572A2 (OSRAM)
CA (1) CA2636854A1 (OSRAM)
CR (1) CR10179A (OSRAM)
EA (1) EA200801515A1 (OSRAM)
IL (1) IL192572A0 (OSRAM)
MA (1) MA30175B1 (OSRAM)
NO (1) NO20082942L (OSRAM)
TW (2) TW200740843A (OSRAM)
WO (1) WO2007085815A2 (OSRAM)
ZA (1) ZA200806202B (OSRAM)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2625664C (en) 2005-10-21 2016-01-05 Novartis Ag Human antibodies against il13 and therapeutic uses
WO2009138413A1 (en) * 2008-05-15 2009-11-19 Domantis Limited Single domain antibodies that bind il-13
WO2007134050A2 (en) * 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US20120039870A9 (en) * 2007-09-07 2012-02-16 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
EP2036980A1 (de) * 2007-09-14 2009-03-18 Gruber, Jens Herabregulation der Genexpression mittels Nukleinsäure-beladener virusähnlicher Partikel
AU2017201007B2 (en) * 2007-10-15 2018-12-13 Sanofi Antibodies that bind IL-4 and/or IL-13 and their uses
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EA201000785A1 (ru) * 2007-12-13 2011-02-28 Глаксо Груп Лимитед Композиции для доставки в легкие
US9181327B2 (en) 2008-01-07 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-HIV domain antibodies and method of making and using same
SG2014014138A (en) * 2008-03-31 2014-07-30 Genentech Inc Compositions and methods for treating and diagnosing asthma
JP2011516603A (ja) 2008-04-17 2011-05-26 アブリンクス エン．ヴェー． 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド
CA2737241C (en) * 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
US20110257373A1 (en) * 2008-10-21 2011-10-20 Rudolf Maria De Wildt Ligands that have binding specificity for dc-sign
PT2356269T (pt) 2008-10-31 2016-09-13 Janssen Biotech Inc Composições, métodos e usos de scaffolds baseados em domínios de fibronectina tipo iii
EA201100653A1 (ru) * 2008-11-26 2011-12-30 Глаксо Груп Лимитед Лиганды, связывающиеся с интерлейкином-13 (il-13)
CA2746395C (en) * 2008-12-10 2019-07-09 Ablynx N.V. Polypeptides comprising amino acid sequences directed against tie 2 for the treatment of diseases and disorders related to angiogenesis
JP5919188B2 (ja) * 2009-05-28 2016-05-18 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｉｌ−１３結合タンパク質
WO2010136483A2 (en) * 2009-05-28 2010-12-02 Glaxo Group Limited Antigen-binding proteins
EA201270174A1 (ru) * 2009-07-16 2012-07-30 Глэксо Груп Лимитед Отдельные связывающиеся вариабельные домены с улучшенными свойствами, направленные против сывороточного альбумина
CA2768981A1 (en) * 2009-07-29 2011-02-03 Rudolf Maria De Wildt Ligands that bind tgf-beta receptor rii
CA2788993A1 (en) 2010-02-05 2011-08-11 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
CN102753148B (zh) 2010-02-11 2018-01-26 埃博灵克斯股份有限公司 用于制备气雾剂的方法和组合物
ES2730693T3 (es) 2010-04-30 2019-11-12 Janssen Biotech Inc Composiciones del dominio de fibronectina estabilizados, métodos y usos
EA201391012A1 (ru) 2011-01-06 2014-01-30 Глэксо Груп Лимитед Лиганды, связывающиеся с рецепторами tgf-бета типа ii
US20130344074A1 (en) 2011-03-16 2013-12-26 Sanofi Uses of a dual v region antibody-like protein
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
EP2699601B1 (en) 2011-04-21 2018-01-17 Bristol-Myers Squibb Company Antibody polypeptides that antagonize cd40
EP3540100B8 (en) 2011-09-27 2022-11-02 Janssen Biotech, Inc. Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces
US10481164B2 (en) * 2012-03-26 2019-11-19 Amgen Inc. Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
SG11201408554QA (en) 2012-06-22 2015-02-27 Cytomx Therapeutics Inc Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
KR102307248B1 (ko) 2012-08-21 2021-10-01 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
CN106986934B (zh) * 2012-08-22 2021-09-14 财团法人牧岩生命工学研究所 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
CA2934004C (en) * 2013-12-17 2023-07-04 The Metrohealth System Compositions and methods for treating fatty tissue buildup
US11066467B2 (en) 2013-12-17 2021-07-20 Mhs Care-Innovation Llc Compositions and methods for treating ischemic heart disease
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
WO2015134988A1 (en) 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
BR112016023238A2 (pt) 2014-04-11 2017-10-17 Novartis Ag processos de tratamento seletivo de asma usando antagonistas de il-13
CN106999420B (zh) 2014-10-10 2021-08-10 埃博灵克斯股份有限公司 用于呼吸系统疾病的气溶胶疗法的吸入装置
US10561805B2 (en) 2014-10-10 2020-02-18 Ablynx N.V. Methods of treating RSV infections
CA2967602C (en) 2014-11-14 2024-09-24 Regeneron Pharmaceuticals, Inc. METHODS OF TREATMENT OF CHRONIC SINUSITIS WITH NASAL POLYPOSIS BY ADMINISTRATION OF AN IL-4R ANTAGONIST
PT3233910T (pt) 2014-12-19 2020-03-17 Ablynx Nv Dímeros de nanocorpos ligados a cisteína
US20190127447A1 (en) 2016-05-02 2019-05-02 Ablynx N.V. Treatment of rsv infection
JP6293829B2 (ja) * 2016-08-05 2018-03-14 モガム インスティチュート フォー バイオメディカル リサーチＭＯＧＡＭ Ｉｎｓｔｉｔｕｔｅ ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ 安定化された免疫グロブリン可変ドメイン選別方法及び選別されたドメインの応用
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
WO2018111976A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Pd-l1 binding fibronectin type iii domains
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
AU2017378226A1 (en) 2016-12-14 2019-06-20 Janssen Biotech, Inc. CD8A-binding fibronectin type III domains
EP4344706A3 (en) 2017-10-30 2024-05-22 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
CN108855003B (zh) * 2018-06-28 2021-01-05 南开大学 一种用于清除血液中炎性因子的免疫吸附剂及其制备方法
CN111514292B (zh) 2018-12-25 2023-06-20 江苏荃信生物医药股份有限公司 抗人白介素4受体α单克隆抗体的制药用途
JP2022541697A (ja) * 2019-02-27 2022-09-27 ジャージャン ナノマブ テクノロジー センター カンパニー リミテッド 高解像度で広範なエピトープを網羅するために、ラクダ科動物抗体を生成する配列ベースのハイスループット法
BR112022000740A2 (pt) 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r
US12491255B2 (en) 2019-10-14 2025-12-09 Aro Biotherapeutics Company EPCAM binding fibronectin type III domains
EP4045061A4 (en) 2019-10-14 2024-04-17 ARO Biotherapeutics Company FIBRONECTIN TYPE III DOMAINS BINDING TO CD137
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
EP4144758A4 (en) 2020-04-22 2024-05-15 Mabwell (Shanghai) Bioscience Co., Ltd. SINGLE VARIABLE DOMAIN ANTIBODIES TARGETING AND DERIVED FROM HUMAN PROGRAMMED DEATH LIGAND 1 (PD-L1)
TW202208428A (zh) 2020-05-06 2022-03-01 美商蜻蜓醫療公司 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質
BR112022022418A2 (pt) * 2020-05-06 2022-12-13 Dragonfly Therapeutics Inc Anticorpos de alvejamento de clec12a e uso dos mesmos
CA3214552A1 (en) 2021-04-14 2022-10-20 Russell C. Addis Cd71 binding fibronectin type iii domains
BR112023021318A2 (pt) 2021-04-14 2023-12-19 Aro Biotherapeutics Company Conjugados de domínio fn3-sirna e usos dos mesmos
MX2024010773A (es) * 2022-03-03 2024-09-10 Pfizer Anticuerpos multiespecificos y usos de estos.
JP2025526875A (ja) * 2022-08-17 2025-08-15 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 改善された抗アルブミンナノボディおよびその使用
JP7668943B2 (ja) * 2023-08-30 2025-04-25 ファイザー・インク 多重特異性抗体およびその使用
JP2025036273A (ja) * 2023-08-30 2025-03-14 ファイザー・インク 多重特異性抗体およびその使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
EP0627002B1 (en) * 1992-02-19 1998-09-23 Schering Corporation Cloning and expression of humanized monoclonal antibodies against human interleukin-4
US5596072A (en) * 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US7175988B2 (en) * 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
EP2135879A3 (en) * 2002-06-28 2010-06-23 Domantis Limited Ligand
CA2511910A1 (en) * 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
EP3718564B1 (en) * 2003-12-23 2023-10-11 Genentech, Inc. Novel anti-il 13 antibodies and uses thereof
AU2005219837A1 (en) * 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. IL-4/IL-13 sepecific polypetides and therapeutic uses thereof
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
JP2008510015A (ja) * 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物

Also Published As

Publication number Publication date
IL192572A0 (en) 2009-02-11
WO2007085815A3 (en) 2007-11-15
US20120093830A1 (en) 2012-04-19
AU2007209202A1 (en) 2007-08-02
ZA200806202B (en) 2009-11-25
BRPI0710572A2 (pt) 2013-01-08
CN101578298A (zh) 2009-11-11
KR20080098382A (ko) 2008-11-07
CR10179A (es) 2008-10-29
NO20082942L (no) 2008-10-15
CA2636854A1 (en) 2007-08-02
US20090060916A1 (en) 2009-03-05
US20110159003A1 (en) 2011-06-30
WO2007085815A2 (en) 2007-08-02
EP1976882A2 (en) 2008-10-08
JP2009523459A (ja) 2009-06-25
TW200740843A (en) 2007-11-01
TW200804593A (en) 2008-01-16
JP2009523460A (ja) 2009-06-25
EA200801515A1 (ru) 2009-02-27
WO2007085815A8 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
MA30175B1 (fr) Ligands qui lient il-4 et/ou il-13
MA30021B1 (fr) Ligands presentant une specificite de liaison avec l'egfr et/ou le vegf et leurs procedes d'utilisation
TW200621805A (en) Anti-ox40l antibodies
WO2006003388A8 (en) Compositions and methods for treating inflammatory disorders
MX337778B (es) Anticuerpos contra il-22 humana y usos para los mismos.
WO2007098420A3 (en) Peptides that block the binding of igg to fcrn
TW200709817A (en) Platform antibody compositions
MA34527B1 (fr) Anticorps contre la metalloproteinase de matrice 9
MA29427B1 (fr) Antagonistes et leurs methodes d'utilisation
MX2010009724A (es) Procedimientos de tratamiento del dolor inflamatorio-.
NO20091926L (no) Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer
TW200744634A (en) Methods of using antibodies against human IL-22
MA30157B1 (fr) Ligands ayant une specificite de liaison pour le vegf et/ou l'egfr et leurs procedes d'utilisation
MX2008011874A (es) Composiciones estabilizadas de polipeptidos.
EA200702128A1 (ru) Фенильные и пиридильные модуляторы lta4h
MX344592B (es) Metodo para eliminar extracorporalmente de la sangre un microbio patogeno, una celula inflamatoria o una proteina inflamatoria.
MA30872B1 (fr) Compositions d'inhibiteurs de la chk1.
MA35174B1 (fr) Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines
WO2003105840A3 (en) Sphingosine kinase inhibitors
WO2008030892A3 (en) Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
DE602005017893D1 (de) Drehverfahren für silikonhydrogel-linsen
DK1261367T3 (da) Anvendelse af interleukin-6-antagonister til behandling af östrogenafhængige tumorer
WO2007111938A3 (en) Inflammation-inhibitory serum factors and uses thereof
WO2007120651A3 (en) Uses and compositions for treatment of juvenile rheumatoid arthritis
NO20084320L (no) Antistoffer mot EGFL7 og fremgangsmater for anvendelse av disse